CorMedix 8-K (7.01, 9.01): Regulation FD disclosure

CorMedix said the FDA accepted for Priority Review its partner Mundipharma’s supplemental application for REZZAYO to prevent invasive fungal disease, setting a target decision date in Q1 2027; if approved, the company aims to begin promotional efforts in the second half of 2027.